Research outlook

Where alcohol use disorder treatment is heading

Alcohol use disorder · Updated Nov 15, 2026

About 28 million Americans have alcohol use disorder, and fewer than 1 in 10 receive treatment. Approved medicines (naltrexone, acamprosate and disulfiram) work but are rarely prescribed; counseling, mutual-help groups and medical withdrawal care are the other pillars. Research is focused on GLP-1 drugs such as semaglutide, which appear to reduce the urge to drink, on psychedelic-assisted therapy, and on starting treatment where people already are, in hospitals and emergency rooms.

  1. Now

    Nov 2026

    GLP-1 drugs reduce drinkingHappened 41.1 point drop in heavy drinking days

    Three randomized trials found semaglutide reduced heavy drinking or craving; in the largest, heavy drinking days fell 41.1 points vs 26.4.

    41.1: percentage-point drop in heavy drinking days, vs 26.4 with placebo.

    Starting naltrexone in hospitalHappened 23.8% heavy drinking days at 3 months

    Started at discharge, naltrexone pills or shots cut heavy drinking days from about 70% to about 25%.

    23.8%: heavy drinking days after 3 months with the injection, from 70.7%.

    Psilocybin shows early promiseHappened 2.78 odds ratio for abstinence

    Across 6 small trials, psilocybin-assisted therapy reduced drinking and raised the odds of abstinence 2.78 times.

    2.78: times higher odds of staying abstinent (odds ratio).

  2. 6 months

    by May 2027

    New targets for craving and sleepPossible

    NIAAA tests apremilast for craving (due January 2027); a VA-linked trial tests suvorexant for sleep in AUD with PTSD (due March 2027).

  3. 12 months

    by Nov 2027

    Does CBD reduce drinking?Possible

    A University of Colorado trial (180 people) compares two CBD products with placebo; due April 2027.

  4. 3 years

    by late 2029

    A Lilly drug in two phase 3 trialsPossible

    Eli Lilly's RENEW-ALC-1 and -2 (2,200 people) test brenipatide, a weekly injection, against placebo for 56 weeks; due April 2028.

    Semaglutide for veteransPossible 41.1 point drop in heavy drinking days

    The VA CRAVE trial (622 veterans) tests semaglutide over 24 weeks; due March 2029.

    41.1: percentage-point drop in heavy drinking days, vs 26.4 with placebo.

    Treatment from the emergency roomPossible

    A Yale trial (240 people) tests starting naltrexone in the emergency department; due August 2028.

  5. 5 years

    by late 2031

    Psychedelic-assisted therapy in phase 3Long shot 2.78 odds ratio for abstinence

    A phase 3 trial in Nîmes, France, tests psilocybin to prevent relapse in AUD with depression (due June 2030); LSD and MDMA trials are also running.

    2.78: times higher odds of staying abstinent (odds ratio).

    A first new approved medicine in decadesLong shot

    If the GLP-1-type trials succeed, a new class of AUD medicine could be submitted for approval.

Happened Likely Possible Long shot

The research paths

Heating up

GLP-1 and gut-hormone drugs

41.1 point drop in heavy drinking days
Details and 4 trialsHide
Early

Psychedelic-assisted therapy

2.78 odds ratio for abstinence
Details and 3 trialsHide
Active

Getting proven medicines to people

23.8% heavy drinking days at 3 months
Details and 1 trialsHide

Starting naltrexone in hospitals and emergency rooms, where many people with AUD are seen.

WatchYale ED trial.

Early

Other new targets

Details and 3 trialsHide

CBD, apremilast, sleep drugs and anti-inflammatory approaches; results so far are mixed.

WatchColorado CBD trial.

Borrowed from other conditions

From Diabetes and obesity

Semaglutide

Phase 3

A GLP-1 drug that reduced heavy drinking days in randomized trials.

From Psoriasis

Apremilast

Phase 2

An oral anti-inflammatory approved for psoriasis, tested for alcohol craving.

From Insomnia

Suvorexant

Phase 2

A sleep medicine that blocks orexin, tested for sleep and drinking in AUD.

Open to join now

See every recruiting Alcohol use disorder trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Apremilast lab studyOther new targets
Jan 2027
Mar 2027
Cannabidiol (CBD)Other new targets
Apr 2027
Brenipatide (RENEW-ALC-1)GLP-1 and gut-hormone drugs
Apr 2028
Brenipatide (RENEW-ALC-2)GLP-1 and gut-hormone drugs
Apr 2028
Tirzepatide, AUD with schizophreniaGLP-1 and gut-hormone drugs
Aug 2028
Medicines started in the emergency departmentGetting proven medicines to people
Aug 2028
LSD treatmentPsychedelic-assisted therapy
Oct 2028
Semaglutide for veterans (CRAVE)GLP-1 and gut-hormone drugs
Mar 2029
May 2030
Jun 2030

What just happened

Review finds early benefit for psilocybin therapy

J Psychopharmacol.

Oral semaglutide reduces heavy drinking days

Am J Psychiatry.

Semaglutide cuts heavy drinking in AUD with obesity

The Lancet.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See Alcohol use disorder trials recruiting now →

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.